Related Experiment Video
Updated: Mar 12, 2026

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
Published on: June 16, 2020
Systemic sarcoidosis first manifesting in a tattoo in the setting of immune checkpoint inhibition
Charissa Kim1, Jianjun Gao1, Vickie R Shannon1
1The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Abstract:
The use of immune checkpoint inhibitors is revolutionising the treatment of cancer. However, their unique toxicity profile is substantially different from what has been observed with traditional chemotherapy, resulting in a novel learning curve for medical oncologists. Early recognition of these toxicities can make a substantial impact in ameliorating these side effects in the oncological and medical-surgical fields. Here, we present a case of Lofgren syndrome sarcoidosis, which first manifested in a tattoo in a patient with metastatic urothelial cancer on therapy with anti-CTLA-4 (ipilimumab) and anti-PD1 (nivolumab).
Related Concept Videos
Drug Toxicity: Allergic Reactions
Hypersensitivity Reactions: Immune-Complex Reactions
Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Tumor Immunotherapy

